According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy (Source: https://www1.racgp.org.au/ajgp/2021/october/medicinal-cannabis)
Australian Health Journal met with 3 speakers at the recent @arcsaustralia ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.
You Might also like
-
Australian Healthcare Week 2019: Pitch Fest Finalist Lumin
Startup company Lumin was a Pitch Fest Finalist at last week’s Australian Healthcare Week Expo in Sydney. The Lumin platform is used in aged care where loneliness and isolation can be a trigger for stroke and dementia. Lumin helps the connection to care providers, family members and duress monitoring services in a device that has been designed for those with dementia, vision impairment or find complex devices difficult to use.
Managing Director and Co-Founder Paul Wilson spoke at the Mepacs booth with Anne Dao from Australian Health Journal about the market they target and the design of the user experience, including the remote servicing and monitoring. The integration allows the monitoring team in the call centre see and hear the personal raising the alarm. Mepacs is a provider of personal duress alarms and have teamed up with Lumin.
Post Views:
1,984 -
Diversity, inclusion and equity New Content Orthopaedic Surgeon People in healthcare Workforce growth
Supporting women in arthroplasty, surgery & orthopaedic oncology
Associate Professor Claudia Di Bella is an academic orthopaedic surgeon based in Melbourne, specialising in orthopaedic oncology and complex joint reconstruction. Originally trained at the world-renowned Rizzoli Orthopaedic Institute (Istituto Ortopedico Rizzoli) in Bologna, Italy, she moved to Australia in 2010 and was awarded Fellowship of the Royal Australasian College of Surgeons in 2013.
-
Report gives insights to clinical trial activity in Australia
Established in 2024, Bellberry is a Adelaide-based national, not-for-profit organisation that provides streamlined scientific and ethical reviews of human research. It is the 2025 winner of the Championing Health Award in the Telstra Best of Business Awards.
Australian Health Journal spoke with Bellberry Limited CEO, Kylie Sproston on the organisation and the findings in activity documented in the Clinical Trial Activity Report (CTAR) 2024.